Theratechnologies - THTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.54
▲ +0.1 (6.95%)

This chart shows the closing price for THTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Theratechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for THTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for THTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Theratechnologies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.54.

This chart shows the closing price for THTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Theratechnologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2024Cantor FitzgeraldReiterated RatingOverweightLow
9/27/2023National Bank FinancialLower TargetC$7.00 ➝ C$5.50Low
8/1/2023National Bank FinancialBoost TargetC$1.75 ➝ C$7.00Low
4/13/2023National Bank FinancialLower TargetC$13.00 ➝ C$9.00Low
1/5/2023Leede Jones GabUpgradeHold ➝ Speculative BuyLow
11/30/2022JonestradingInitiated CoverageBuyLow
11/17/2022Cantor FitzgeraldInitiated CoverageOverweight$36.00Low
7/15/2022National Bank FinancialLower TargetC$15.00 ➝ C$13.00Low
2/26/2021Leede Jones GabDowngradeSpeculative Buy ➝ HoldLow
1/31/2021Royal Bank of CanadaReiterated RatingHold$8.00Low
10/16/2020MackieReiterated RatingBuy$18.00High
7/20/2020Royal Bank of CanadaReiterated RatingHold$8.00Low
7/8/2020Echelon Wealth PartnersReiterated RatingBuy$44.00High
2/25/2020MackieReiterated RatingBuy$23.20Low
12/11/2019MackieUpgradeHold ➝ BuyLow
10/9/2019Royal Bank of CanadaSet TargetHold$6.00Low
10/9/2019MackieReiterated RatingHoldN/A
(Data available from 7/16/2019 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/18/2024
  • 0 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/17/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/17/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/16/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/16/2024

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Theratechnologies logo
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: $1.54
Low: $1.45
High: $1.56

50 Day Range

MA: $1.31
Low: $1.17
High: $1.55

52 Week Range

Now: $1.54
Low: $0.88
High: $3.44

Volume

43,083 shs

Average Volume

50,251 shs

Market Capitalization

$70.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Theratechnologies?

The following Wall Street analysts have issued stock ratings on Theratechnologies in the last twelve months: Cantor Fitzgerald, and National Bank Financial.
View the latest analyst ratings for THTX.

What is the current price target for Theratechnologies?

0 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Theratechnologies in the next year.
View the latest price targets for THTX.

What is the current consensus analyst rating for Theratechnologies?

Theratechnologies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe THTX will outperform the market and that investors should add to their positions of Theratechnologies.
View the latest ratings for THTX.

What other companies compete with Theratechnologies?

How do I contact Theratechnologies' investor relations team?

Theratechnologies' physical mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The company's listed phone number is (514) 336-7800 and its investor relations email address is [email protected]. The official website for Theratechnologies is www.theratech.com. Learn More about contacing Theratechnologies investor relations.